CDKN2A and glioma: By leveraging the superior sensitivity of next-generation DNA sequencing [29] with semi-quantitative scoring methodologies and digital pathology, our study puts forward specific threshold values for p16 expression as a surrogate marker of CDKN2A HD status, enabling greater standardization of this cost-effective tool in glioma diagnostics.